ArticleOncology letters2026
Single-center retrospective study of factors associated with early discontinuation of tumor-treating fields therapy in glioblastoma.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is the most aggressive primary malignant tumor of the adult central nervous system with poor survival outcomes despite multimodal standard treatment. Tumor-treating fields (TTFields) therapy prolongs survival in patients with newly diagnosed GBM; however, sustained adherence is essential to achieve therapeutic benefits. The risk factors for early discontinuation of TTFields remain poorly understood, as patients with treatment durations of <2-3 months have been typically excluded from previous analyses. In the present single-center retrospective study, the clinical and molecular factors associated with early discontinuation of TTFields were investigated in 16 consecutive adult patients with supratentorial GBM treated between September 2019 and February 2025. Early discontinuation was defined as the cessation of treatment within 90 days without resumption. Clinical variables, activities of daily living, neurocognitive assessments and molecular profiles were evaluated. Early discontinuation occurred in five patients (31.3%). Comparative analysis revealed that hemiparesis at treatment initiation (P=0.018), attentional impairment (P=0.036), lower baseline Karnofsky performance status (P=0.005) and Barthel Index (P=0.013) were significantly more frequent in the early discontinuation group than in the continuation group. Furthermore, overall survival was significantly shorter in the early discontinuation group (hazard ratio 8.857, 95% confidence interval 1.56-50.29, P=0.004), and progression-free survival showed a non-significant trend toward a shorter duration. No significant differences were found in the other neurocognitive test scores or molecular alterations. These findings indicated that specific neurological deficits and functional impairments may hinder treatment persistence. Therefore, early identification of at-risk patients and implementation of supportive strategies, including enhanced caregiver involvement and welfare support, may improve adherence and optimize the clinical benefits of TTFields in GBM.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.